Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameining and liver function in outpatients with depressive disorder
ChiCTR2300075209Phase 4Not yet recruiting
- Sponsor
- Chaohu Hospital of Anhui Medical University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), anxiety disorder, sleep disorder and 1 more, sponsored by Chaohu Hospital of Anhui Medical University. Primary endpoints: ALT and AST. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)anxiety disordersleep disorderSomatic symptom and related disorders (SSRD)
Beyond the preview
Go deeper on ChiCTR2300075209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075209.